How to access Tagrisso from India — the named-patient import pathway, 2026
By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23
An Indian patient newly diagnosed with EGFR-mutant non-small-cell lung cancer (NSCLC) may receive a prescription for Tagrisso (osimertinib) from their treating medical oncologist after EGFR testing confirms an actionable mutation (exon 19 deletion, L858R, or T790M). Tagrisso is FDA-approved in the United States and is considered first-line standard of care for EGFR-mutant advanced NSCLC. In India, brand-form Tagrisso may not always be the product the family's oncologist prefers — some patients or physicians specifically request the US-sourced brand for quality-chain assurance, which is why your oncologist may be coordinating a personal-import pathway on your behalf.
This guide explains the legal pathway, what documentation your physician needs, typical timing and cost bands, and where Reserve Meds fits in.
The clinical situation
Tagrisso is a third-generation oral EGFR tyrosine kinase inhibitor that selectively targets sensitising EGFR mutations and the T790M resistance mutation while sparing wild-type EGFR. Eligibility requires molecular confirmation of an EGFR mutation from tumour tissue or plasma (liquid biopsy). The manufacturer is AstraZeneca. Dosing is typically 80 mg orally once daily as continuous therapy, with adjustments or interruptions for toxicity (diarrhoea, rash, QTc prolongation, rare pneumonitis). Your oncologist will confirm mutation status and sequencing against your overall treatment plan.
Is Tagrisso legally importable into India?
Yes — through the personal-import provision recognised under the Drugs and Cosmetics Act and the framework administered by the Central Drugs Standard Control Organization (CDSCO). The framework allows a patient, through their treating physician, to import a quantity of a medicine for personal use when the medicine has been approved by a recognised foreign regulator (FDA qualifies) and is prescribed for their named clinical need.
The named-patient mechanism rests on four anchors: (a) the medicine is approved by a recognised reference authority such as the FDA, (b) no clinically equivalent locally registered alternative is suitable for the patient as judged by the physician, (c) the treating physician takes clinical responsibility for use, and (d) the importing party documents chain of custody from the US source to the patient. Supporting documentation typically includes the physician's prescription, a clinical rationale letter, and customs declaration.
How the pathway works, step by step
- Consultation with your treating oncologist. The decision to prescribe Tagrisso is a clinical one, based on EGFR mutation results and line of therapy. Your oncologist documents the rationale.
- Prescription and clinical rationale letter. Your physician issues a prescription naming Tagrisso and the planned duration (typically a three-month personal-use quantity per shipment).
- Personal-import documentation. Reserve Meds prepares the personal-import package for customs clearance, including the physician letter, prescription, patient identifier, and product chain-of-custody.
- US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from the manufacturer's authorised distribution chain under DSCSA.
- Temperature-controlled shipment. Tagrisso is a stable oral tablet; shipments travel with tamper-evident packaging and customs documentation end to end.
- Arrival and dispensing support. Your oncologist remains the treating clinician. Reserve Meds coordinates re-supply ahead of cycle end to avoid treatment gaps.
What documentation your physician needs
Your physician will typically need to provide:
- A clinical rationale letter confirming EGFR mutation status, prior therapies, and Tagrisso as the indicated treatment
- Verification of their Indian medical registration (state medical council)
- A current prescription naming the product, strength, and quantity
- Patient identifier (the family's preferred anonymised reference where possible)
- The planned treatment cadence (typically continuous daily therapy with monthly re-supply)
Reserve Meds provides a physician documentation kit bundling the templates Indian customs and CDSCO reviewers expect to see for personal-import of oncology oral therapies. Your oncologist does not need prior named-patient experience; the kit is designed to make first-time coordination straightforward.
Costs and timing
Tagrisso's US cash-pay reference price for a 30-day supply sits in an indicative 2026 range of roughly USD 16,000–19,000. A full personal-import shipment typically covers one to three months of therapy. Logistics, customs handling, and concierge coordination add incremental cost; Reserve Meds issues a full transparent quote at the start of intake.
Indicative timing — not guaranteed — for first shipment arrival after cohort intake opens is approximately 14–28 days from the moment a complete dossier is assembled. Subsequent re-supply cycles are generally faster once the pathway is established with your physician and the receiving address.
Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.
Reserve Meds's role
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Tagrisso specifically, we provide:
- Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
- Documentation. Personal-import documentation package for your physician and for Indian customs handling.
- Logistics. Temperature-stable shipment coordination and customs clearance support.
- Concierge case lead. A named point of contact for your family and your physician throughout the process.
What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating oncologist. We operate on a waitlist basis during our pre-launch phase.
Frequently asked
Is this legal in India? Yes, when executed through the personal-import provision under the Drugs and Cosmetics Act with appropriate physician documentation. The provision has supported cross-border access to specialty oncology therapies for many years. See our trust and compliance page for our methodology.
What about locally-available generics? Indian generic osimertinib is available at substantially lower cost. The personal-import pathway is selected by families who specifically want the US-sourced AstraZeneca brand for quality-chain assurance; the choice is yours and your oncologist's. We support the decision, we do not influence it.
Will private insurance cover this? Cash-pay is the default. Some Indian private insurers reimburse named-patient imports on case-by-case approval; we supply documentation for your submission but do not process insurance claims directly.
What happens if I miss a refill window? Our re-supply cadence is scheduled proactively at roughly Day 20 of each cycle so the next shipment arrives before current stock runs out. Flag any travel or scheduling change early and we re-time accordingly.
Next step — join the first-cohort waitlist
Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Tagrisso coordination in India.
Add me to the Tagrisso waitlist> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.
Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.